{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:34:00Z","timestamp":1790775240582,"version":"4.1.0"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,11,8]],"date-time":"2016-11-08T00:00:00Z","timestamp":1478563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bcmd.2016.10.005","type":"journal-article","created":{"date-parts":[[2016,10,20]],"date-time":"2016-10-20T23:07:10Z","timestamp":1477004830000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"special_numbering":"C","title":["Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase"],"prefix":"10.1016","volume":"68","author":[{"given":"Ari","family":"Zimran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derlis Emilio","family":"Gonzalez-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Abrahamov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter A.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheeba","family":"Varughese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Giraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milan","family":"Petakov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ee Shien","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul","family":"Chertkoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2016.10.005_bb0005","series-title":"Williams Hematology","first-page":"1121","article-title":"Gaucher disease and related lysosomal storage diseases","author":"Zimran","year":"2016"},{"key":"10.1016\/j.bcmd.2016.10.005_bb0010","series-title":"The Online Metabolic and Molecular Basis of Inherited Disease","first-page":"1","article-title":"Gaucher disease","author":"Grabowski","year":"2010"},{"key":"10.1016\/j.bcmd.2016.10.005_bb0015","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/00005792-199211000-00002","article-title":"Gaucher disease. Clinical, laboratory, radiologic, and genetic features of 53 patients","volume":"71","author":"Zimran","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcmd.2016.10.005_bb0020","first-page":"565","article-title":"Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy","volume":"86","author":"Zevin","year":"1993","journal-title":"Q. J. Med."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0025","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jpeds.2003.10.067","article-title":"Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations","volume":"144","author":"Charrow","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0030","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00431-003-1362-0","article-title":"Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements","volume":"163","author":"Grabowski","year":"2004","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0035","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1001\/archpedi.160.6.603","article-title":"The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis","volume":"160","author":"Kaplan","year":"2006","journal-title":"Arch. Pediatr. Adolesc. Med."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0040","series-title":"Elelyso","year":"2015"},{"key":"10.1016\/j.bcmd.2016.10.005_bb0045","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nbt0612-472","article-title":"First plant-made biologic approved","volume":"30","author":"Fox","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0050","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1111\/j.1467-7652.2007.00263.x","article-title":"Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system","volume":"5","author":"Shaaltiel","year":"2007","journal-title":"Plant Biotechnol. J."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0055","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.bcmd.2014.10.002","article-title":"Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease","volume":"54","author":"Zimran","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0060","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.bcmd.2014.05.004","volume":"53","author":"Pastores","year":"2014","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bcmd.2010.10.009","article-title":"Improving the accuracy of MRI spleen and liver volume measurements: a phase III Gaucher disease clinical trial setting as a model","volume":"46","author":"Bracoud","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0070","series-title":"Child Health Questionnaire\u2122 (CHQ) PF-28","year":"2013"},{"key":"10.1016\/j.bcmd.2016.10.005_bb0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.jaci.2005.12.1303","article-title":"Second symposium on the definition and management of anaphylaxis: summary report\u2013Second National Institute of Allergy and Infectious Disease\/Food Allergy and Anaphylaxis Network symposium","volume":"117","author":"Sampson","year":"2006","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0080","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1542\/peds.2007-2144","article-title":"Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1","volume":"122","author":"Andersson","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.bcmd.2016.10.005_bb0085","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.ymgme.2015.05.012","article-title":"Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naive to enzyme replacement therapy or previously treated with imiglucerase","volume":"117","author":"Smith","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0090","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/ajh.24369","article-title":"Long-term efficacy and safety results of taliglucerase alfa up to 36months in adult treatment-naive patients with Gaucher disease","volume":"91","author":"Zimran","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0095","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/ajh.24399","article-title":"Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase","volume":"91","author":"Pastores","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0100","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.bcmd.2010.10.011","article-title":"Osteopenia in Gaucher disease develops early in life: response to imiglucerase enzyme therapy in children, adolescents and adults","volume":"46","author":"Mistry","year":"2011","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0105","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1067\/mpd.2001.112171","article-title":"The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease","volume":"138","author":"Altarescu","year":"2001","journal-title":"J. Pediatr."},{"key":"10.1016\/j.bcmd.2016.10.005_bb0110","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1007\/s10545-009-1164-2","article-title":"Management of neuronopathic Gaucher disease: revised recommendations","volume":"32","author":"Vellodi","year":"2009","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1079979616302212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:34:20Z","timestamp":1761050060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1079979616302212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":22,"alternative-id":["S1079979616302212"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.005","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term safety and efficacy of taliglucerase alfa in pediatric Gaucher disease patients who were treatment-na\u00efve or previously treated with imiglucerase","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2016.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}